Management
The Amphion management team has significant experience in nurturing companies through all stages of their growth adopting a hands-on approach to operating as an extension of their management teams. Collectively, the team has created and developed more than 30 technology-driven companies in the information technology, physical and life sciences industries. Our public companies have included Celgene, Medisense, SEQUUS, Quidel, Macromedia, Veritas, Vortech Data, Santa Cruz Operation, and AXCESS.
The core team has been together nearly 20 years. During this period of time we have successfully raised over $230 million for principal investing activities and assisted our partner companies in raising over $500 million in both private and public transactions. We have created over $20 billion in market value.
Richard C. E. Morgan, Chief Executive Officer
Robert J. Bertoldi, President and Chief Financial Officer
Dr. Faisal H. S. Al-Refaei, Special Advisor
John A. Caruso, Managing Director
Raymond P. McKenzie, Senior Advisor
Jerel Whittingham, Managing Director
Richard C. E. Morgan, CEO
Over the course of his career, Mr. Morgan has been directly involved in the start-up and development of more than 35 companies in the information technology, healthcare, and biotechnology industries. Mr. Morgan was a founder and CEO of Amphion Capital Partners LLC (the predecessor company to Amphion Innovations). He was also the Managing General Partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP) a position which he retains, although the partnership is no longer active.
Before joining Wolfensohn, Mr. Morgan spent 15 years with Schroders plc, a British merchant bank, where he was a member of the board of the merchant bank and head of the Schroder Strategy Group, which he founded. Mr. Morgan, a British citizen, was raised in Kenya and educated in England. He graduated with a B. Engineering First Class Honors from the University of Auckland, New Zealand. In 1982 he completed the Advanced Management Program at the Harvard Business School.
Robert J. Bertoldi, President and Chief Financial Officer
Prior to his involvement with the Company, Mr. Bertoldi was a founder President and CFO of Amphion Capital Partners LLC (the predecessor company) and VennWorks LLC. Mr. Bertoldi is also a general partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP).
Prior to that, he served as Chief Financial Officer for James D. Wolfensohn, Inc. and Hambro America Inc. He began his career at KPMG and left as a manager in the investment services department. Mr. Bertoldi received a B.A. in Accounting and Economics from Queens College, New York in 1976 and became a Certified Public Accountant in 1978. He is a member of the AICPA and NYSCPA.
Dr. Faisal H.S. Al-Refaei, Special Advisor
Dr. Al-Refaei works on extending Amphion's business ties to the Middle East and managing the day-to-day activities of Amphion and its Partner Companies in the region.
Dr. Al-Refaei has over 7 years of healthcare-sector experience and operational experience in building and managing companies in the Middle East. Dr. Al-Refaei is the co-founder and CEO of Saydanah, an Amphion Partner Company under establishment. Dr. Al-Refaei has completed his Masters Degree in Healthcare Management (Distinction) from the University of Wales, Swansea. He received his Bachelor's Degree in Medicine and Surgery (MBChB) from Aberdeen University, Scotland, for which he received The Amiri Honorary Medal for Scientific Achievement from the Kuwaiti Government.
John A. Caruso, Managing Director
Mr. Caruso is a Managing Director of Amphion Innovations US, Inc. and leads its intellectual property efforts. He brings over 25 years of experience in IP, start-up activities, and general and FDA counsel and business roles.
Mr. Caruso was an associate with the Fish and Neave patent law firm, a patent attorney with Bristol-Myers Squibb and Baxter International, and General Counsel of Enzon Pharmaceuticals and Reckitt Benckiser Pharmaceuticals. Additionally, he has had business roles of Vice President Regulatory Affairs and Business Development in the pharmaceutical industry. Mr. Caruso has served as a consultant to and board member of biotech, start-up companies. Mr. Caruso is a graduate of Ohio State University with a BSc. in Physiology, and of Cleveland State University Law School.
Raymond P. McKenzie, Senior Advisor
Mr. McKenzie is a senior advisor for Amphion Innovations. He is a private investor who specializes in co-investing with proven private equity and venture capital value creators. Mr. McKenzie is a board member of the following Amphion companies: FireStar Software, PrivateMarkets, m2m Imaging Corp., and Suvani.
Prior to this Mr. McKenzie spent 16 years working in Investment Banking in New York City with Lazard Frères & Co. in Fixed Income & Capital Markets from 1985-1998 where he was a Vice President and previously with Morgan Stanley & Co., Inc. from 1983-1985. He received an A.B. degree from Dartmouth College, NH where he majored in Physics. Mr. McKenzie is a dual national of Barbados and Great Britain. He is also fluent in French, Italian & Spanish.
Jerel Whittingham, Managing Director
Mr. Whittingham is a Board member and Managing Director of Amphion Innovations UK Ltd and leads their activities in the UK. He has extensive technology commercialisation experience in investor, start-up and opportunity development roles with companies including Amphion, VennWorks, Generics Group PLC, Durlacher PLC, and a materials science start-up.
He has worked on commercialisation projects at number of universities and leading European companies in diverse areas including media technologies, biosensors, diagnostics, materials science, and medical imaging. Mr. Whittingham has spoken at a number of conferences and chaired sessions of both Nanomed and the World Nano-Economic Forum. His commitment to company building in the tech sector builds on earlier career experience in R&D and then strategy development roles. He is a graduate of London, Cranfield, and Brussels Universities and is also on the boards of Amphion Innovations UK Ltd, of Kromek, Ltd, where he chairs the compensation committee, and of Myconostica Ltd where he is currently CEO.
